Trial Profile
Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in dialysis patients. Monitorering af forskelle ved behandling af Chronic Kidney Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2020
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Renal failure
- Focus Pharmacodynamics
- Acronyms MAVA
- 07 Jan 2020 Status changed from recruiting to discontinued.
- 04 Oct 2017 New trial record